Out now @moltherapy.bsky.social Methods & Clin Dev‬: We show that CAR T-cell biology is shaped not just by CAR design but also by engineering method. Sleeping Beauty vs lentiviral platforms imprinted distinct activation & exhaustion-like states - important for future CAR T optimization. Read at👇

Congrats to Mascha Binder & her team @binderlab.bsky.social‬ on their new paper showing that blood-based inflammation markers-like IL-6 & cfDNA-are better than PD-L1 at predicting immunotherapy outcomes in head & neck cancer.A move toward smarter, tailored treatments. www.nature.com/articles/s41...

Tmem127-mediated immune receptor degradation regulates T cell homeostasis through the common gamma chain https://www.biorxiv.org/content/10.1101/2025.07.01.662281v1

Tmem127-mediated immune receptor degradation regulates T cell homeostasis through the common gamma chain https://www.biorxiv.org/content/10.1101/2025.07.01.662281v1

Our latest work: The immunoproteasome disturbs neuronal metabolism and drives neurodegeneration in multiple sclerosis: Cell www.cell.com/cell/fulltex...

Excited to co-found and help lead @imprintlabs.bsky.social —a focused effort to decode the immune system’s memory through cutting-edge computation and experimentation. Grateful to be on this journey with an exceptional team.

Online Now: UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial

Excited to share our latest study on DADA2. We analyzed 52 patients, observing HGG, loss of T & B cell memory and persistent proinflammatory cytokines despite anti-TNF therapy. Notably, the B cell architecture was skewed toward IGHV4-34, a feature often seen in malignant B cells.

Binder Lab: Immune Changes & Lymphoma Risk 🔬 DADA2 mutations disrupt immune balance—low antibodies, memory B/T loss & inflammation. binderlab.bsky.social links IGHV4-34 B cells to autoimmunity & lymphoma. Their ML tool detects DADA2 via immune architecture! 📖 More: www.jacionline.org/article/S009...

IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia https://www.biorxiv.org/content/10.1101/2025.02.04.636461v1

Very happy to see this finally out @bioRxiv: We generated a bispecific antibody targeting the IGLV3-21-R110 CLL-specific driver mutation. Read here: www.biorxiv.org/content/10.1...

Happy to share our new preprint reporting a direct comparison of transposon-based and lentiviral CAR T cell manufacturing approaches. Read at @biorxivpreprint.bsky.social . doi.org/10.1101/2025...